NEW YORK, March 14, 2017 -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Rentech, Inc. securities (NASDAQ:RTK) from November 9, 2016 through February 20, 2017, both dates inclusive (the “Class Period”). The lawsuit seeks to recover damages for Rentech investors under the federal securities laws.
To join the Rentech class action, go to http://www.rosenlegal.com/cases-1057.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) Rentech’s resources were not sufficient to overcome any operating challenges and remaining bottleneck at the Wawa facility; (2) consequently, the Wawa facility would not reach approximately 60% of production capacity within the next couple quarters and achieve full capacity in the range of 400,000 to 450,000 metric tons late in the year; (3) as a result, defendants’ statements about Rentech’s business, operations and prospects were materially false and misleading and/or lacked a reasonable bases at all relevant times. On February 21, 2017, Rentech announced its decision to idle the Wawa facility due to equipment and operational issues that would require additional unbudgeted capital investment. On this news, shares of Rentech fell $1.31 per share or over 47% from its previous closing price to close at $1.44 per share on February 21, 2017, damaging investors.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 24, 2017. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-1057.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected].
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] [email protected] www.rosenlegal.com


ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China
Bain Capital Moves to Acquire Majority Stake in Echo Marketing
Grok AI Faces Global Scrutiny Over Safeguard Failures and Illegal Content on X
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro
U.S. Airline Flight Cancellations Surge After Venezuela Military Operation and FAA Airspace Closures
Samsung Signals Comeback With HBM4 Chips as AI Market Heats Up
Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026
NextEra Energy Stock Rises After Reaffirming Earnings and Dividend Growth Outlook
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies
Tesla Poised for Breakout Year in 2026 as New Products and EV Market Reset Drive Growth
Neuralink Plans High-Volume Brain Implant Production and Fully Automated Surgery by 2026
Reddit Emerges as a Major Winner in the Shift to AI-Powered Search
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change
Drugmakers Plan 2026 U.S. Price Increases on Over 350 Branded Medications Despite Political Pressure
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 



